[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
QueenBioInvestor posts on X about $ipsc, $bmyorbital, $bmy, cart the most. They currently have XXX followers and X posts still getting attention that total XX engagements in the last XX hours.
Social category influence stocks XX%
Social topic influence $ipsc #9, $bmyorbital 20%, $bmy 20%, cart 20%, $coya 20%, $sgmo 20%, $tlsa 20%, breaking news 20%, has been 20%, $dnli XX%
Top accounts mentioned or mentioned by @nexttradex @biotech2k1
Top assets mentioned Bristol-Myers Squibb Co (BMY) Denali Therapeutics Inc. Common Stock (DNLI) Alnylam Pharmaceuticals, Inc. (ALNY) CRISPR Therapeutics AG (CRSP) Intellia Therapeutics, Inc (NTLA) uniQure N.V. (QURE)
Top posts by engagements in the last XX hours
"@NextTradeX no one knows which modality wins. Thats why I size small and wait for proof. $IPSC may be cheap but it still needs clinical traction in autoimmune and clean mfg. Ill buy capitulation and treat $BMY/Orbital as a sector tailwind not a 1:1 read-through"
X Link @QueenBioInvest 2025-10-10T12:50Z XXX followers, XXX engagements
"@NextTradeX Yes but different tech. Orbital is in-vivo CAR-T with circular RNA delivered by LNPs (preclin). $IPSC develops allogeneic iPSC-derived NK/T cells ex-vivo now pivoting to autoimmune (CD19). Same immune reset theme different modality and risk. $BMY buying platform optionality"
X Link @QueenBioInvest 2025-10-10T11:22Z XXX followers, XXX engagements
"Nobel day for immune tolerance Congrats to Mary Brunkow Fred Ramsdell (co-founder & former CSO at Sonoma Biotherapeutics) and Shimon Sakaguchi. Public plays on Tregs/tolerance: $COYA (LD-IL-2/Treg-enhancing) $SGMO (CAR-Treg TX200) $TLSA (intranasal anti-CD3 to induce Tregs)"
X Link @QueenBioInvest 2025-10-06T17:26Z XXX followers, 3611 engagements
"@Biotech2k1 Im with you on $DNLI. Starter on todays dip; plan is add on pullbacks into the pre-PDUFA window. The $ALNY comparison makes sense platform + path can rerate fast"
X Link @QueenBioInvest 2025-10-10T15:54Z XXX followers, XXX engagements
"@Biotech2k1 I respect the COGS/payer risks but I dont avoid whole modalities. With the right setup (data + mfg + payer clarity) GT/editing can work see $CRSP/$NTLA momentum $QURE post-HD. I trade price and near catalysts with tight sizing"
X Link @QueenBioInvest 2025-10-10T11:11Z XXX followers, XXX engagements